The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Open accessAbstract
Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR screen we identified the bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. BRD9 is a component of SS18-SSX containing BAF complexes in synovial sarcoma cells; and integration of BRD9 into these complexes is critical for cell growth. Moreover BRD9 and SS18-SSX co-localize extensively on the synovial sarcoma genome. Remarkably, synovial sarcoma cells are highly sensitive to a novel small molecule degrader of BRD9, while other sarcoma subtypes are unaffected. Degradation of BRD9 induces downregulation of oncogenic transcriptional programs and inhibits tumour progression in vivo. We demonstrate that BRD9 supports oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 1×
“Moreover, SEs drive expression of genes required for maintaining tumour cell identity (Hnisz et al., 2013; Lovén et al., 2013).”
BackgroundSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationComprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Gene expression profiling of human sarcomas: insights into sarcoma biology.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1699 · Cited by 353
Smits, A. H., Jansen, P. W. T. C., Poser, I., Hyman, A. A., & Vermeulen, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks941 · Cited by 258
Self-citation
Research works printed but not linked: 44
- Alpsoy, 2018, Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes, Journal of Biological Chemistry, 293, 3892, 10.1074/jbc.RA117.001065 · DOI · Paper page
- Anderson, 2012, Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities, Pediatric Research, 72, 112, 10.1038/pr.2012.54 · DOI
- Banito, 2018, The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma, Cancer Cell, 33, 527, 10.1016/j.ccell.2018.01.018 · DOI
- Barretina, 2010, Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy, Nature Genetics, 42, 715, 10.1038/ng.619 · DOI · Paper page
- Brien, 2015, A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence, Genes & Development, 29, 2231, 10.1101/gad.267930.115 · DOI
- Brien, 2016, Exploiting the epigenome to control cancer-promoting gene-expression programs, Cancer Cell, 29, 464, 10.1016/j.ccell.2016.03.007 · DOI
- Brohl, 2014, The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation, PLOS Genetics, 10, e1004475, 10.1371/journal.pgen.1004475 · DOI · Paper page
- Burningham, 2012, The epidemiology of sarcoma, Clinical Sarcoma Research, 2, 14, 10.1186/2045-3329-2-14 · DOI · Paper page
- Cai, 2015, Drugging chromatin in cancer: recent advances and novel approaches, Molecular Cell, 60, 561, 10.1016/j.molcel.2015.10.042 · DOI
- Cancer Genome Atlas Research Network, 2017, Comprehensive and integrated genomic characterization of adult soft tissue sarcomas, Cell, 171, 950, 10.1016/j.cell.2017.10.014 · DOI · Paper page
- Clark, 1994, Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma, Nature Genetics, 7, 502, 10.1038/ng0894-502 · DOI · Paper page
- Crompton, 2014, The genomic landscape of pediatric Ewing sarcoma, Cancer Discovery, 4, 1326, 10.1158/2159-8290.CD-13-1037 · DOI · Paper page
- de Leeuw, 1995, Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas, Human Molecular Genetics, 4, 1097, 10.1093/hmg/4.6.1097 · DOI · Paper page
- Francis, 2007, Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential, BMC Genomics, 8, 73, 10.1186/1471-2164-8-73 · DOI · Paper page
- Gao, 2018, Driver fusions and their implications in the development and treatment of human cancers, Cell Reports, 23, 227, 10.1016/j.celrep.2018.03.050 · DOI · Paper page
- Haldar, 2007, A conditional mouse model of synovial sarcoma: insights into a myogenic origin, Cancer Cell, 11, 375, 10.1016/j.ccr.2007.01.016 · DOI · Paper page
- Hensel, 2016, Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma, Oncotarget, 7, 1451, 10.18632/oncotarget.6385 · DOI
- Hohmann, 2016, Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition, Nature Chemical Biology, 12, 672, 10.1038/nchembio.2115 · DOI · Paper page
- Kadoch, 2013, Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma, Cell, 153, 71, 10.1016/j.cell.2013.02.036 · DOI · Paper page
- Kadoch, 2013, Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy, Nature Genetics, 45, 592, 10.1038/ng.2628 · DOI · Paper page
- Kadoch, 2017, Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states, Nature Genetics, 49, 213, 10.1038/ng.3734 · DOI · Paper page
- Krämer, 2017, BRD9 inhibition, alone or in combination with cytostatic compounds as a therapeutic approach in rhabdoid tumors, International Journal of Molecular Sciences, 18, 1537, 10.3390/ijms18071537 · DOI
- Lee, 2014, Twist1 is essential in maintaining mesenchymal state and tumor-initiating properties in synovial sarcoma, Cancer Letters, 343, 62, 10.1016/j.canlet.2013.09.013 · DOI
- Lerdrup, 2016, An interactive environment for agile analysis and visualization of ChIP-sequencing data, Nature Structural & Molecular Biology, 23, 349, 10.1038/nsmb.3180 · DOI · Paper page
- Lim, 1998, A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas, Oncogene, 17, 2013, 10.1038/sj.onc.1202122 · DOI
- Martin, 2016, Structure-Based design of an in vivo active selective BRD9 inhibitor, Journal of Medicinal Chemistry, 59, 4462, 10.1021/acs.jmedchem.5b01865 · DOI · Paper page
- McBride, 2018, The SS18-SSX fusion oncoprotein hijacks baf complex targeting and function to drive synovial sarcoma, Cancer Cell, 33, 1128, 10.1016/j.ccell.2018.05.002 · DOI · Paper page
- McDonald, 2017, Project DRIVE: A compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep rnai screening, Cell, 170, 577, 10.1016/j.cell.2017.07.005 · DOI · Paper page
- Middeljans, 2012, SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes, PLOS ONE, 7, e33834, 10.1371/journal.pone.0033834 · DOI
- Rappsilber, 2007, Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips, Nature Protocols, 2, 1896, 10.1038/nprot.2007.261 · DOI · Paper page
- Remillard, 2017, Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands, Angewandte Chemie International Edition, 56, 5738, 10.1002/anie.201611281 · DOI · Paper page
- Sarver, 2015, Identification, by systematic RNA sequencing, of novel candidate biomarkers and therapeutic targets in human soft tissue tumors, Laboratory Investigation, 95, 1077, 10.1038/labinvest.2015.80 · DOI
- Savic, 2015, CETCh-seq: CRISPR epitope tagging ChIP-seq of DNA-binding proteins, Genome Research, 25, 1581, 10.1101/gr.193540.115 · DOI
- Seki, 2015, Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma, Nature Communications, 6, 7557, 10.1038/ncomms8557 · DOI · Paper page
- Shern, 2014, Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors, Cancer Discovery, 4, 216, 10.1158/2159-8290.CD-13-0639 · DOI · Paper page
- Shi, 2014, The mechanisms behind the therapeutic activity of BET bromodomain inhibition, Molecular Cell, 54, 728, 10.1016/j.molcel.2014.05.016 · DOI · Paper page
- Shi, 2015, Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains, Nature Biotechnology, 33, 661, 10.1038/nbt.3235 · DOI · Paper page
- Skytting, 1999, A Novel Fusion Gene, SYT – SSX4 in Synovial Sarcoma fusion messenger RNA in biopsy speci, Journal of the National Cancer Institute, 91, 4, 10.1093/jnci/91.11.974 · doi:10.1093/jnci/91.11.974
- Soulez, 1999, SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex, Oncogene, 18, 2739, 10.1038/sj.onc.1202613 · DOI
- Su, 2012, Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics, Cancer Cell, 21, 333, 10.1016/j.ccr.2012.01.010 · DOI
- Takahashi, 2014, Analysis of gene expression profiles of soft tissue sarcoma using a combination of knowledge-based filtering with integration of multiple statistics, PLOS ONE, 9, e106801, 10.1371/journal.pone.0106801 · DOI
- Terry, 2007, TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies, The American Journal of Surgical Pathology, 31, 240, 10.1097/01.pas.0000213330.71745.39 · DOI · Paper page
- Theodoulou, 2016, Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition, Journal of Medicinal Chemistry, 59, 1425, 10.1021/acs.jmedchem.5b00256 · DOI · Paper page
- Tirode, 2014, Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations, Cancer Discovery, 4, 1342, 10.1158/2159-8290.CD-14-0622 · DOI · Paper page
Cited by
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
The SWI/SNF complex in cancer — biology, biomarkers and therapy
Mittal, P., & Roberts, C. W. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0357-3 · Cited by 690
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies
Centore, R. C., Sandoval, G. J., Soares, L. M. M., Kadoch, C., & Chan, H. M. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.07.011 · Cited by 387
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 337
Metadata
- Authors
- Brien, G. L., Remillard, D., Shi, J., Hemming, M. L., Chabon, J., Wynne, K., Dillon, E. T., Cagney, G., Van Mierlo, G., Baltissen, M. P., Vermeulen, M., Qi, J., Fröhling, S., Gray, N. S., Bradner, J. E., Vakoc, C. R., & Armstrong, S. A.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2018-11-15
- Volume
- 7
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W2900693695
- Cited by
- 213
- References
- 8
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0/ (am)
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- National Cancer Institute (CA176745, CA066996, CA204915)
- Alex's Lemonade Stand Foundation for Childhood Cancer
- European Molecular Biology Organization (ALTF-1235-2015)
- Irish Cancer Society (CRF18BRI)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. https://app.cochat.ai/papers/10.7554/elife.41305
- The paper
- Brien, G. L., Remillard, D., Shi, J., Hemming, M. L., Chabon, J., Wynne, K., Dillon, E. T., Cagney, G., Van Mierlo, G., Baltissen, M. P., Vermeulen, M., Qi, J., Fröhling, S., Gray, N. S., Bradner, J. E., Vakoc, C. R., & Armstrong, S. A. (2018). Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. eLife. https://doi.org/10.7554/elife.41305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.